What Дазолик treats: Main Uses and Benefits

This medication is commonly used to manage infections caused by susceptible protozoa and anaerobic bacteria; it is applied when symptoms create noticeable physiological strain. It is considered relevant in managing conditions such as Amoebiasis (including severe intestinal and extra-intestinal forms), Giardiasis (Lambliasis), and genitourinary infections like Trichomoniasis and bacterial vaginosis. It also assists with deep-seated anaerobic infections and is applied in clinical settings that involve acute or unstable symptom patterns. The medication is relevant across domains where additional symptomatic support is needed.

Quick Fact: Symptomatic Support for Gastrointestinal Distress This medicine is commonly used to help with acute symptoms like infectious diarrhea and abdominal cramping associated with parasitic diseases.

“The medication supports the patient during difficult episodes by easing distress and is applied in scenarios where additional management of discomfort is required.”

Ornidazole is also commonly used as surgical prophylaxis prior to high-risk procedures (e.g., colorectal or gynecological surgery) to assist with managing the risk of postoperative anaerobic infection, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

1. Medsafe New Zealand data sheet

Official Population Eligibility for Дазолик (Ornidazole)

The eligibility for using Ornidazole is strictly defined by regulatory documents, which establish specific criteria for permitted, restricted, or prohibited use based on population group and pre-existing conditions.

Category	Regulatory Status	Constraint / Condition
Absolute Contraindications	Prohibited	Known hypersensitivity to Ornidazole or other nitroimidazole derivatives [Source 1.4]. Patients with organic central nervous system disorders (e.g., epilepsy, multiple sclerosis) [Source 1.6, 2.5].
Age-Related Eligibility	Use Established	Authorized for adults and children. Pediatric use requires weight-based calculations for children under 35 kg [Source 1.2].
Organ Function Restriction	Restricted Use	Severe hepatic impairment requires the dosing interval to be doubled due to prolonged clearance [Source 1.2, 3.6]. Haemodialysis requires an additional dose after each session [Source 1.2].
Reproductive Status	Not Recommended	Early pregnancy (first trimester) and lactation are generally not recommended due to lack of controlled human data [Source 1.7, 2.3].

The regulatory profile prohibits use based on immunological contraindications and instability of the central nervous system. Use is made conditional for populations with compromised liver function or kidney function requiring dialysis, which affects drug elimination. Use in the very young and during reproductive phases is officially restricted or discouraged.

Interactions with other medicines and products

Official regulatory documents define specific substance interactions for Ornidazole (Дазолик), categorized by their effect on drug exposure and pharmacodynamic outcomes.

Contraindicated Combination and Timing Rule

The co-ingestion of Alcohol (Ethanol) is strictly restricted due to the risk of a disulfiram-like reaction. This mandatory rule requires that alcohol must be avoided during the course of Ornidazole therapy and for a period of at least 3 days following the final dose.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance	Official Interaction Outcome
Coumarin-type Oral Anticoagulants (e.g., Warfarin)	Potentiation of the anticoagulant effect, described as a possible increase in coagulation test results (PT/INR).
Vecuronium Bromide	Prolongation of the muscle relaxant effect.
Lithium	May increase the plasma levels of lithium.
5-Fluorouracil	May reduce the clearance of 5-fluorouracil, leading to a risk of toxicity.
Cimetidine	May prolong the half-life and decrease the plasma clearance of Ornidazole.
Phenobarbital / Phenytoin	May reduce the half-life of Ornidazole.

Population-Specific Interaction Note

In patients with Hepatic Impairment (liver cirrhosis), the elimination half-life of Ornidazole is intrinsically prolonged, and plasma clearance is lower. This altered pharmacokinetic profile is noted by regulatory agencies as a factor that may increase the potential for drug accumulation and interaction with co-administered medicines.

Reductive Activation: The Pathogen's Self-Destruct Switch

Дазолик (Ornidazole) functions as a chemically inert prodrug that requires activation by specific microbial systems. This process is dependent on the low redox potential enzymes (like ferredoxins) and the anaerobic (low-oxygen) environment found exclusively within susceptible pathogens. These enzymes chemically reduce the drug's core nitro group ( NO2), initiating the cytotoxic process exclusively within the pathogen, which confers selective toxicity to the mechanism.

Genetic Destruction: DNA Strand Breakage

Following activation, the process yields highly volatile nitro free radicals and other reactive intermediates. These toxic species rapidly and irreversibly damage the microbial DNA by causing strand breakage and structural destabilization. This molecular chaos leads directly to the ultimate physiological consequence: the bactericidal and protozoacidal effect (killing) due to the resultant inhibition of the pathogen's ability to replicate and synthesize essential proteins, resulting in the functional elimination of the target organism populations.

Official Administration Guidelines

The use of Ornidazole (Дазолик) is governed by specific instructions detailing the routes of administration, dose ranges, and timing constraints.

Administration Routes and Forms

The medicine is prepared for administration via oral film-coated tablets (typically 500 mg strength), as a sterile solution for intravenous infusion (0.5% w/v), and as a vaginal pessary for localized application. The tablets must be taken during or immediately after a meal to align with standard instructions.

Standard Dosage and Timing

For adults, regimens often specify a single oral dose of 1.5 g (1500 mg) for short courses, or a maintenance pattern of 500 mg twice daily, with treatment durations typically ranging from 1 to 10 days. Intravenous administration, generally used for more severe courses, begins with a 0.5 g to 1 g initial dose followed by 500 mg every 12 hours. The IV solution must be diluted to 5 mg/mL or less and infused slowly over 15 to 30 minutes.

Special Population Rules

Specific procedural adjustments are required for certain populations. For individuals with severe hepatic impairment, the standard dosing interval must be doubled. Patients undergoing haemodialysis require an additional supplementary dose before the procedure, although general renal impairment does not necessitate a dose adjustment. Furthermore, pediatric dosing for children under 35 kg is determined by body weight, and the regimen for Trichomoniasis requires that the sexual partner be treated concomitantly using the same oral dosage.

Research Evidence / Overview of Studies for Дазолик (Ornidazole)

---

Evidence for Use in Common Protozoal Infections (Giardiasis and Trichomoniasis)

The research exploring the use of Дазолик for treating common protozoal infections, such as Giardiasis and Trichomoniasis, largely consists of Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies focused on measuring key short-term outcomes related to systemic or functional imbalance. Specifically, researchers examined the parasitological cure rate—meaning the clearance of the infectious organism—and changes in patient-reported outcomes describing perceived discomfort. The research explored short-term symptom changes in adult patients diagnosed with Trichomonas vaginalis and in both adults and children diagnosed with Giardia lamblia.

Findings describe patterns observed in the studies, which often described measurements of organism clearance in the studied populations. Research highlights changes measured during the study period, with many trials reporting how symptoms evolved in the observed groups following administration. While the existing body of evidence is well-documented for these short-term measurements, follow-up durations were limited in many of the trials. This means there is limited information for long-term outcomes and what the follow-up studies measured regarding recurrence.

---

Evidence for Use in Amoebiasis and Bacterial Vaginosis (BV)

Research exploring the use of Ornidazole for Amoebiasis and Bacterial Vaginosis (BV) involves Comparative Clinical Trials and reviews. For Amoebiasis, studies monitored outcomes capturing phases of heightened symptom activity, such as changes in clinical symptoms and the microbiological clearance of the Entamoeba histolytica organism. For BV, research examined outcomes related to physical discomfort and was evaluated in adult women, focusing on changes in established diagnostic scores and rates of subsequent recurrence.

For Amoebiasis, the data show patterns related to the clearance of the parasite and changes in gastrointestinal symptoms. Research exploring the use of Ornidazole is acknowledged in the broader scientific literature. However, evidence quality varies across studies, as some of the clinical trials reflect earlier methodologies that predate current standardization practices. Regarding BV, studies report how symptoms evolved in the observed populations, but a significant finding that applies to all BV treatments is that recurrence was frequently measured in the follow-up periods.

---

What is Still Uncertain About the Research for Дазолик

The current research contributes to the broader evidence landscape but does not determine whether an individual will respond similarly. One key limitation is that evidence quality varies across studies, particularly due to the inclusion of older trials that predate modern rigorous reporting standards. The sample sizes were modest in several comparative trials, limiting the ability to draw highly precise conclusions for some localized anaerobic infections. Furthermore, long-term outcomes are not fully established across most indications, as the focus of the core trials was typically on short-term clearance and symptom resolution.

Common questions about Дазолик (FAQ)

Q: What is Дазолик used for?

Дазолик (Azithromycin) is an antibiotic used to treat a wide variety of bacterial infections. It belongs to a class of drugs called macrolide antibiotics.

It is commonly prescribed for:

• Respiratory tract infections (like pneumonia and bronchitis)
• Skin and soft tissue infections
• Ear infections (otitis media)
• Sexually transmitted infections (STIs) caused by certain bacteria

Q: How should I take Дазолик?

Always follow your healthcare provider's instructions exactly when taking Дазолик.

• Dosage: The dose and duration of treatment depend on the type and severity of the infection being treated.
• With or Without Food: In most cases, Дазолик can be taken with or without food. However, some formulations (like the extended-release suspension) must be taken on an empty stomach.
• Completing the Course: It is crucial to finish the full course of antibiotics prescribed, even if your symptoms improve before the medicine is gone. Stopping early can allow bacteria to continue growing, which may lead to a relapse of the infection or the development of antibiotic resistance.

Q: What are the common side effects of Дазолик?

Like all medications, Дазолик can cause side effects. Most are mild and temporary.

Common side effects often affect the stomach and bowels:

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain

Less common, but important side effects can include:

• Headache
• Dizziness
• Changes in taste
• Mild skin rash

If you experience severe or persistent side effects, contact your healthcare provider immediately.

Q: Can Дазолик cause heart problems?

Дазолик has been associated with a small risk of changes in the heart’s electrical activity, specifically prolongation of the QT interval.

This risk is generally low, but it is increased in people who:

• Already have a slow heart rate or other existing heart rhythm problems.
• Have low potassium or magnesium levels.
• Are taking other medications that can also prolong the QT interval.

If you have a history of heart issues, it is important to discuss this with your doctor before starting Дазолик. If you experience signs of an abnormal heart rhythm (like a pounding or fluttering heartbeat, or fainting), seek medical attention right away.

Q: Can I drink alcohol while taking Дазолик?

There is no known severe drug-alcohol interaction specifically with Дазолик (Azithromycin).

However, it is generally advised to limit or avoid alcohol consumption while you are ill and taking any antibiotic. Alcohol can:

• Worsen side effects like nausea and dizziness.
• Dehydrate the body.
• Potentially slow down your recovery from the infection.

Follow your doctor's recommendations regarding alcohol use during your treatment.

Storage Conditions

Ornidazole tablets must be stored under specific conditions to maintain quality. The medication requires storage at a temperature not exceeding 30 C (86 F), and must be protected from both light and moisture.

Requirement	Official Regulatory Statement
Temperature Limit	Store at a temperature not exceeding 30 C (86 F).
Protection	Must be protected from light and moisture.
Container Rule	Keep the tablets in the blister pack until consumption.
Prohibited Areas	Do not store in damp environments, such as a bathroom, or in areas subject to excessive heat, like window sills.

All forms of Dazolik must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Ornidazole product must be performed in accordance with local requirements for medicinal waste. The product must not be allowed to enter sewers or surface water, as it is an antimicrobial agent. Consult the pharmacist for guidance on safe and authorized methods for discarding leftover medication.